Simulations Plus, Inc. (NASDAQ: SLP)

$13.65 ▲ +0.08 (+0.59%)

As of May 14, 2026 12:12 PM

Sector: Healthcare Industry: Health Information Services CIK: 0001023459

Market Cap 273.54 Mn

P/E -4.34

P/S 3.40

Div. Yield 0.00

ROIC (Qtr) 0.00

Revenue Growth (1y) (Qtr) 8.29

Add ratio to table...

About

Simulations Plus, Inc. is a company that provides modeling and simulation software and related services to the pharmaceutical and biotechnology industries to support drug development. The company's solutions enable clients to accelerate the discovery and development of new therapeutics, reduce research and development costs, comply with regulatory requirements, and improve confidence in drug safety and efficacy. Simulations Plus operates through a remote work culture with headquarters in Research Triangle Park, North Carolina, and a European office...

Simulations Plus, Inc. is a company that provides modeling and simulation software and related services to the pharmaceutical and biotechnology industries to support drug development. The company's solutions enable clients to accelerate the discovery and development of new therapeutics, reduce research and development costs, comply with regulatory requirements, and improve confidence in drug safety and efficacy. Simulations Plus operates through a remote work culture with headquarters in Research Triangle Park, North Carolina, and a European office in Paris, France.

Simulations Plus generates revenue primarily from the sale of software licenses and the provision of consulting and implementation services. Software revenue comes from the sale of perpetual and term licenses for its modeling and simulation platforms used across the drug development lifecycle. Service revenue is derived from professional services including consulting, training, customization, and support for clients utilizing the company's software solutions. The company serves pharmaceutical and biotechnology companies engaged in drug discovery, development, and commercialization activities.

The company operates through the following segments: Software and Services.

• The Software segment includes the development, licensing, and maintenance of proprietary modeling and simulation software products used in drug discovery, development, and clinical trial planning. These products support activities such as pharmacokinetics, pharmacodynamics, formulation development, and drug-drug interaction analysis. Revenue in this segment is generated from software licenses, updates, and technical support.

• The Services segment provides professional services including consulting, implementation, training, and customization of the company's software solutions for clients. These services help pharmaceutical companies apply modeling and simulation techniques to their specific drug development projects, ensuring proper use of the software and integration into their research workflows. Revenue in this segment is derived from time-and-materials engagements and fixed-fee projects.

Simulations Plus holds a specialized position in the pharmaceutical technology industry as a provider of model-informed drug development (MIDD) software and services. The company competes with other firms offering simulation and modeling tools for drug development, though it differentiates itself through its long-standing focus on pharmaceutical applications, validated scientific engines, and integrated workflow capabilities across the drug development lifecycle. Competitive advantages include proprietary scientific algorithms, regulatory expertise, and a track record of supporting regulatory submissions and approvals.

The company serves pharmaceutical and biotechnology companies engaged in drug research and development. Its customer base includes organizations involved in small molecule and biologic drug discovery, preclinical development, clinical trial design, and regulatory submission processes. Specific customer names are not disclosed in the filing.

Investment thesis

Bull case

Simulations Plus has moved decisively from a collection of standalone modeling tools to a fully integrated product ecosystem that spans discovery, development, clinical operations, and commercialization. The company has engineered seamless interoperability across its core engines—GastroPlus, MonolixSuite, ADMET Predictor, and QSP platforms—by leveraging a cloud‑scale S+ Cloud foundation and AI‑driven workflows. This convergence allows clients to run end‑to‑end simulations and regulatory submissions within a single environment, dramatically reducing data silos and turnaround times. As a result, the company can command higher value from each customer and create new upsell opportunities that were impossible under its fragmented product architecture.
The rollout of AI‑accelerated features has already begun to shift pricing dynamics in the company’s favor. By embedding AI capabilities into the base models, Simulations Plus can justify incremental price increases that reflect the added value of faster, more accurate predictions. Early customer feedback has been positive, suggesting that the market is willing to absorb modest premium pricing in exchange for tangible productivity gains. This willingness to pay provides a strong tailwind for future revenue growth without a corresponding surge in cost. The company’s plan to monetize AI modules in the near future further reinforces this upside.
Services revenue has grown 16% in the quarter, driven by a 42% jump in commercialization services and an 8% rise in development services. The backlog for services projects rose 18% to $20.4 million, indicating that customer demand is not only sustained but also expanding. The management narrative that services act as a leading indicator for software adoption is supported by the observation that as clients free up discretionary budgets, they often expand their internal modeling teams and purchase additional software licenses. This cyclical relationship between services and software is a reliable engine for cross‑selling and margin enhancement.
Macro‑economic conditions have begun to normalize for the biopharma sector. Tariff fears have eased, and most‑favoured‑nation pricing agreements are progressing, which has reduced cost uncertainty for clients. Concurrently, the biopharma funding environment is improving, providing sponsors with more capital to invest in early‑stage discovery tools. These favorable conditions are reflected in the “acceleration in year‑end spending” noted by the CEO, suggesting that future quarters may see a shift toward higher software spend as sponsors move from discretionary services to long‑term licenses.
From a financial health perspective, the company is well capitalized with $35.7 million in cash and short‑term investments, and it maintains a clean balance sheet with no debt. Strong free cash flow allows the firm to invest heavily in R&D and AI initiatives without compromising liquidity. The ability to fund innovation internally reduces reliance on external financing, preserving financial flexibility in an uncertain macro environment. The management guidance of 26% to 30% adjusted EBITDA margin for FY 2026 indicates that the company is on track to sustain high profitability.

Simulations Plus has moved decisively from a collection of standalone modeling tools to a fully integrated product ecosystem that spans discovery, development, clinical operations, and commercialization. The company has engineered seamless interoperability across its core engines—GastroPlus, MonolixSuite, ADMET Predictor, and QSP platforms—by leveraging a cloud‑scale S+ Cloud foundation and AI‑driven workflows. This convergence allows clients to run end‑to‑end simulations and regulatory submissions within a single environment, dramatically reducing data silos and turnaround times. As a result, the company can command higher value from each customer and create new upsell opportunities that were impossible under its fragmented product architecture.
The rollout of AI‑accelerated features has already begun to shift pricing dynamics in the company’s favor. By embedding AI capabilities into the base models, Simulations Plus can justify incremental price increases that reflect the added value of faster, more accurate predictions. Early customer feedback has been positive, suggesting that the market is willing to absorb modest premium pricing in exchange for tangible productivity gains. This willingness to pay provides a strong tailwind for future revenue growth without a corresponding surge in cost. The company’s plan to monetize AI modules in the near future further reinforces this upside.
Services revenue has grown 16% in the quarter, driven by a 42% jump in commercialization services and an 8% rise in development services. The backlog for services projects rose 18% to $20.4 million, indicating that customer demand is not only sustained but also expanding. The management narrative that services act as a leading indicator for software adoption is supported by the observation that as clients free up discretionary budgets, they often expand their internal modeling teams and purchase additional software licenses. This cyclical relationship between services and software is a reliable engine for cross‑selling and margin enhancement.
Macro‑economic conditions have begun to normalize for the biopharma sector. Tariff fears have eased, and most‑favoured‑nation pricing agreements are progressing, which has reduced cost uncertainty for clients. Concurrently, the biopharma funding environment is improving, providing sponsors with more capital to invest in early‑stage discovery tools. These favorable conditions are reflected in the “acceleration in year‑end spending” noted by the CEO, suggesting that future quarters may see a shift toward higher software spend as sponsors move from discretionary services to long‑term licenses.
From a financial health perspective, the company is well capitalized with $35.7 million in cash and short‑term investments, and it maintains a clean balance sheet with no debt. Strong free cash flow allows the firm to invest heavily in R&D and AI initiatives without compromising liquidity. The ability to fund innovation internally reduces reliance on external financing, preserving financial flexibility in an uncertain macro environment. The management guidance of 26% to 30% adjusted EBITDA margin for FY 2026 indicates that the company is on track to sustain high profitability.

Bear case

Software revenue declined 17% year‑to‑quarter, a sharp contraction that reflects weakening demand in the discovery and clinical operations segments. Discovery products represent only 15% of the software mix, and the company's most lucrative development products—GastroPlus and MonolixSuite—account for 81% of software revenue, leaving little cushion if these core offerings lose market share. A 17% decline in software highlights a vulnerability to shifts in customer budgets, especially as large pharma continues to consolidate and rationalize spend.
The company’s QSP licensing model relies heavily on perpetual therapeutic model sales, a business that is inherently lumpy and cyclical. The management response to the QSP question acknowledged that quarterly revenue is uneven due to the timing of model sales, which can lead to volatile earnings. Relying on a high‑margin but low‑frequency revenue stream exposes the company to timing risk and complicates forecasting, especially in a market where new therapeutic areas are emerging but not yet generating consistent licensing activity.
Consolidation among large pharmaceutical companies has emerged as a persistent headwind, as evidenced by the CEO’s admission that consolidation has pressured software renewals, particularly in the back half of FY 2025. Large sponsors merging or acquiring smaller entities often renegotiate or reduce their spend on modeling tools to streamline operations. This trend could accelerate, eroding the company’s high‑margin software base and forcing it to compete on price or lose customers altogether.
While services gross margin increased to 36% from 26%, the underlying cost base remains elevated due to a reorganization that shifted personnel to product development. The shift left the services organization with higher labor costs relative to billable revenue, creating pressure on margin sustainability. Additionally, services are inherently cyclical and sensitive to client budgets, meaning that a downturn in R&D spending could lead to a rapid decline in service income, which would offset software gains.
R&D expenses have climbed to 15% to 17% of revenue, a significant rise that could erode profitability if not offset by higher margin software or services. The company’s capitalized software expense—about 20% of work—will generate amortization charges that will pressure earnings in the coming periods. If the anticipated product releases fail to capture the market, the company may face a double hit from higher operating expenses and lower revenue growth.

Software revenue declined 17% year‑to‑quarter, a sharp contraction that reflects weakening demand in the discovery and clinical operations segments. Discovery products represent only 15% of the software mix, and the company's most lucrative development products—GastroPlus and MonolixSuite—account for 81% of software revenue, leaving little cushion if these core offerings lose market share. A 17% decline in software highlights a vulnerability to shifts in customer budgets, especially as large pharma continues to consolidate and rationalize spend.
The company’s QSP licensing model relies heavily on perpetual therapeutic model sales, a business that is inherently lumpy and cyclical. The management response to the QSP question acknowledged that quarterly revenue is uneven due to the timing of model sales, which can lead to volatile earnings. Relying on a high‑margin but low‑frequency revenue stream exposes the company to timing risk and complicates forecasting, especially in a market where new therapeutic areas are emerging but not yet generating consistent licensing activity.
Consolidation among large pharmaceutical companies has emerged as a persistent headwind, as evidenced by the CEO’s admission that consolidation has pressured software renewals, particularly in the back half of FY 2025. Large sponsors merging or acquiring smaller entities often renegotiate or reduce their spend on modeling tools to streamline operations. This trend could accelerate, eroding the company’s high‑margin software base and forcing it to compete on price or lose customers altogether.
While services gross margin increased to 36% from 26%, the underlying cost base remains elevated due to a reorganization that shifted personnel to product development. The shift left the services organization with higher labor costs relative to billable revenue, creating pressure on margin sustainability. Additionally, services are inherently cyclical and sensitive to client budgets, meaning that a downturn in R&D spending could lead to a rapid decline in service income, which would offset software gains.
R&D expenses have climbed to 15% to 17% of revenue, a significant rise that could erode profitability if not offset by higher margin software or services. The company’s capitalized software expense—about 20% of work—will generate amortization charges that will pressure earnings in the coming periods. If the anticipated product releases fail to capture the market, the company may face a double hit from higher operating expenses and lower revenue growth.

Segments Breakdown of Revenue (2025)

Peer comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	GEHC	GE HealthCare Technologies Inc.	28.30 Bn	14.85	1.35	10.13 Bn
2	VEEV	Veeva Systems Inc	25.58 Bn	28.11	8.01	-
3	BTSG	BrightSpring Health Services, Inc.	11.57 Bn	54.88	0.85	2.50 Bn
4	HQY	Healthequity, Inc.	7.08 Bn	33.00	5.39	0.96 Bn
5	DOCS	Doximity, Inc.	4.41 Bn	18.51	6.91	-
6	WAY	Waystar Holding Corp.	3.58 Bn	26.69	3.10	1.47 Bn
7	HNGE	Hinge Health, Inc.	2.95 Bn	-6.00	5.07	-
8	PRVA	Privia Health Group, Inc.	2.76 Bn	118.95	1.30	-

Research Tools

Simulations Plus, Inc. (NASDAQ: SLP)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password